Cancer Immunotherapy Market Expands with Checkpoint Inhibitors and Personalized Therapies | Merck & Co., Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, AstraZeneca

Cancer Immunotherapy Market reached US$ 137.70 billion in 2024 and is expected to reach US$ 261.74 billion by 2033, growing at a CAGR of 7.9% during the forecast period 2025-2033.

Cancer immunotherapy harnesses the immune system to target and destroy cancer cells. This market is expanding rapidly, driven by breakthroughs in immune checkpoint inhibitors, CAR-T cell therapies, and personalized vaccines. With approvals for multiple cancers and growing clinical trials, immunotherapy is becoming a mainstay in oncology treatment.

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/cancer-immunotherapy-market?ophp

Cancer immunotherapy harnesses the immune system to target and destroy cancer cells. This market is expanding rapidly, driven by breakthroughs in immune checkpoint inhibitors, CAR-T cell therapies, and personalized vaccines. With approvals for multiple cancers and growing clinical trials, immunotherapy is becoming a mainstay in oncology treatment.

Cancer Immunotherapy Market Competitors Overview:

Merck & Co., Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Kite Pharma, Inc., Dendreon Pharmaceuticals, and Amgen Inc., among others.

Important Industry Updates of 2023, 2024 and 2025:

✅ In April 2025, Akeso, Inc. announced that the China's National Medical Products Administration (NMPA) has approved the supplemental new drug application for ivonescimab. This immunotherapy drug is a first-in-class PD-1/VEGF bispecific antibody approved for use as a monotherapy for the first-line treatment of PD-L1-positive non-small cell lung cancer (NSCLC), who have negative EGFR and ALK gene mutations.

✅ In September 2024, MSD (known as Merck in the U.S. and Canada) has announced the approval of Keytruda (pembrolizumab) in Japan for certain non-small cell lung carcinoma (NSCLC) and radically unresectable urothelial carcinoma patients.

Methodology and Scope

The Cancer Immunotherapy Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cancer-immunotherapy-market?ophp

Cancer Immunotherapy Market Segments Overview:

∎ By Type (Immune Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Adoptive Cell Therapy, Other Immunotherapies)
∎ By Indication (Non-Small Cell Lung Cancer (NSCLC), Melanoma, Colorectal Cancer, Renal Cell Carcinoma, Breast Cancer, Bladder Cancer, Others)

The immune checkpoint inhibitors segment dominates the market, driven by their proven success in treating multiple cancers with durable responses and growing approvals

Regional Overview for Cancer Immunotherapy Market:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

North America leads due to high immuno-oncology drug approvals and clinical trial activity. Asia Pacific is the fastest growing, driven by rising cancer incidence and growing access to novel therapies.

Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=cancer-immunotherapy-market?ophp

The Report Covers:

➡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
➡ Strategic recommendations with a focused go-to-market approach.
➡ An unbiased evaluation of overall market performance.
➡ Region- and country-specific insights, with customized reports available upon request.
➡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.

People Also Ask:

➤ What are the current global trends in sales, production, imports, and exports within the Cancer Immunotherapy market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the Cancer Immunotherapy market?

Unlock 360° Market Intelligence with 2 Days FREE Trial Access of DataM Subscription Now!: https://www.datamintelligence.com/reports-subscription?ophp

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.